01177 SINO BIOPHARM
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 1.26X | Oper Margin | 25.6% |
|---|---|---|---|
| LT Debt/Equity | 6.5% | Net Margin | 12.1% |
| Total Debt/Equity | 30.4% | Return on Equity | 11.0% |
| Price/Book | 3.80X | Return on Assets | 5.4% |
| (HKD 6.880) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 3,722.07 | 2,570.26 | 2,851.85 | 17,867.55 | 3,288.72 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +44.8 | -9.9 | -84.0 | +443.3 | +6.5 |
| Earnings Per Share (HKD) | 0.204 | 0.139 | 0.153 | 0.952 | 0.175 |
| Earnings Per Share Growth (%) | +46.7 | -9.4 | -83.9 | +444.3 | +6.6 |
| Dividend Per Share (HKD) | 0.070 | 0.050 | 0.120 | 0.080 | 0.073 |
| P/E* (X) | 33.81 | 49.60 | 44.94 | 7.23 | 39.34 |
| Yield (%) | 1.02 | 0.73 | 1.74 | 1.16 | 1.07 |
| Dividend Share (%) | 34.40 | 36.05 | 78.38 | 8.40 | 41.91 |
| Book NAV (HKD) | 1.809 | 1.787 | 1.773 | 1.967 | 1.054 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-21 21:40:20
Latest Result
| (RMBMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 28,919 | 27,982 | +3.3 | 28,780 |
| Operating Result | 5,866 | 6,165 | -4.8 | 5,928 |
| Associates | -118.299 | -525.71 | -77.5 | -152.976 |
| Profit Before Taxation | 6,994 | 5,934 | +17.9 | 5,779 |
| Taxation | 629.693 | 836.181 | -24.7 | 775.986 |
| Profit /( Loss) After Taxation | 6,365 | 5,097 | +24.9 | 5,003 |
| Minority Interests | 2,865 | 2,765 | +3.6 | 2,459 |
| Net Profit | 3,500 | 2,332 | +50.1 | 2,544 |
| Earnings Per Share () | 0.2035 | 0.1387 | +46.7 | 0.1531 |
| Dividend Per Share () | 0.0700 | 0.0500 | +40.0 | 0.1200 |
| Announcement Date | 2025-03-20 | 2024-03-28 | NA | 2023-03-31 |
* Annualised
Last Update Time: 2025-07-21 21:40:25
